company background image

Santen Pharmaceutical TSE:4536 Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials +
4536 fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance4/6
Financial Health6/6

4536 Stock Overview

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally.

Santen Pharmaceutical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Santen Pharmaceutical
Historical stock prices
Current Share PriceJP¥1,058.00
52 Week HighJP¥1,718.00
52 Week LowJP¥968.00
1 Month Change-1.86%
3 Month Change-1.58%
1 Year Change-28.99%
3 Year Change-41.25%
5 Year Change-37.98%
Change since IPO242.03%

Recent News & Updates

Shareholder Returns

4536JP PharmaceuticalsJP Market

Return vs Industry: 4536 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4536 underperformed the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4536's price volatile compared to industry and market?
4536 volatility
4536 Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4536 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.

About the Company

18904,315Shigeo Taniuchi

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis.

Santen Pharmaceutical Fundamentals Summary

How do Santen Pharmaceutical's earnings and revenue compare to its market cap?
4536 fundamental statistics
Market CapJP¥415.98b
Earnings (TTM)JP¥26.53b
Revenue (TTM)JP¥266.80b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4536 income statement (TTM)
Cost of RevenueJP¥111.15b
Gross ProfitJP¥155.65b
Other ExpensesJP¥129.12b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)67.48
Gross Margin58.34%
Net Profit Margin9.95%
Debt/Equity Ratio0.0%

How did 4536 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks
When do you need to buy 4536 by to receive an upcoming dividend?
Santen Pharmaceutical dividend dates
Ex Dividend DateSep 29 2022
Dividend Pay DateNov 30 2022
Days until Ex dividend52 days
Days until Dividend pay date114 days

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is 4536 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4536?

Other financial metrics that can be useful for relative valuation.

4536 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA6.6x
PEG Ratio4.2x

Price to Earnings Ratio vs Peers

How does 4536's PE Ratio compare to its peers?

4536 PE Ratio vs Peers
The above table shows the PE ratio for 4536 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average15.8x
4506 Sumitomo Pharma
4581 Taisho Pharmaceutical Holdings
4516 Nippon Shinyaku
4540 Tsumura
4536 Santen Pharmaceutical

Price-To-Earnings vs Peers: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (15.8x).

Price to Earnings Ratio vs Industry

How does 4536's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the JP Pharmaceuticals industry average (17.4x)

Price to Earnings Ratio vs Fair Ratio

What is 4536's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4536 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.7x
Fair PE Ratio19.6x

Price-To-Earnings vs Fair Ratio: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (19.6x).

Share Price vs Fair Value

What is the Fair Price of 4536 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4536 (¥1058) is trading below our estimate of fair value (¥1643.78)

Significantly Below Fair Value: 4536 is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Future Growth

How is Santen Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4536's forecast earnings growth (3.7% per year) is above the savings rate (0.04%).

Earnings vs Market: 4536's earnings (3.7% per year) are forecast to grow slower than the JP market (8.6% per year).

High Growth Earnings: 4536's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4536's revenue is expected to decline over the next 3 years (-1.3% per year).

High Growth Revenue: 4536's revenue is forecast to decline over the next 3 years (-1.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4536's Return on Equity is forecast to be low in 3 years time (7.1%).

Discover growth companies

Past Performance

How has Santen Pharmaceutical performed over the past 5 years?

Past Performance Score


Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4536 has high quality earnings.

Growing Profit Margin: 4536's current net profit margins (9.9%) are higher than last year (3.1%).

Past Earnings Growth Analysis

Earnings Trend: 4536's earnings have declined by 15.5% per year over the past 5 years.

Accelerating Growth: 4536's earnings growth over the past year (232.6%) exceeds its 5-year average (-15.5% per year).

Earnings vs Industry: 4536 earnings growth over the past year (232.6%) exceeded the Pharmaceuticals industry 17.2%.

Return on Equity

High ROE: 4536's Return on Equity (7.7%) is considered low.

Discover strong past performing companies

Financial Health

How is Santen Pharmaceutical's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4536's short term assets (¥218.7B) exceed its short term liabilities (¥88.1B).

Long Term Liabilities: 4536's short term assets (¥218.7B) exceed its long term liabilities (¥30.3B).

Debt to Equity History and Analysis

Debt Level: 4536 is debt free.

Reducing Debt: 4536 had no debt 5 years ago.

Debt Coverage: 4536 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4536 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Santen Pharmaceutical current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 07 2022Ex Dividend DateSep 29 2022Dividend Pay DateNov 30 202262 days from Ex DividendBuy in the next 52 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4536's dividend (3.02%) is higher than the bottom 25% of dividend payers in the JP market (1.63%).

High Dividend: 4536's dividend (3.02%) is low compared to the top 25% of dividend payers in the JP market (3.62%).

Stability and Growth of Payments

Stable Dividend: 4536's dividends per share have been stable in the past 10 years.

Growing Dividend: 4536's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (48.1%), 4536's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (146.8%), 4536's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Shigeo Taniuchi (49 yo)





Mr. Shigeo Taniuchi has been President of Santen Pharmaceutical Co., Ltd. since April 1, 2018 and serves as its Chief Executive Officer since April 01, 2020 and served as Head of Human Resources Division u...

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Shigeo's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Insufficient data to compare Shigeo's compensation with company performance.

Leadership Team

Experienced Management: 4536's management team is considered experienced (2.1 years average tenure).

Board Members

Experienced Board: 4536's board of directors are considered experienced (3.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Santen Pharmaceutical Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Santen Pharmaceutical Co., Ltd.
  • Ticker: 4536
  • Exchange: TSE
  • Founded: 1890
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: JP¥415.983b
  • Shares outstanding: 393.18m
  • Website:

Number of Employees


  • Santen Pharmaceutical Co., Ltd.
  • Grand Front Osaka Tower A
  • 4-20 Ofuka-cho
  • Osaka
  • 530-8552
  • Japan


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.